Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
M. Bolla(Centre Hospitalier Universitaire de Grenoble), Laurence Collette(GlaxoSmithKline (Belgium)), Theo M. de Reijke(Amsterdam University Medical Centers), L. Da Pozzo, Bertrand Tombal(Cliniques Universitaires Saint-Luc), Marc Colombel(Hôpital Edouard Herriot), Pierre Scalliet, Geertjan van Tienhoven, A. Verbaeys(Ghent University Hospital), Alphonsus van den Bergh(University Medical Center Groningen), Jean-François Bosset(Université de Franche-Comté), Karin Haustermans(Radboud University Nijmegen), K. Vekemans(Hartcentrum Hasselt), Thomas Gasser(Hertie Institute for Clinical Brain Research), Roland van Velthoven(Institut Jules Bordet), Paul C.M.S. Verhagen(Erasmus University Rotterdam), C. van de Beek(Maastricht University Medical Centre), Cora N. Sternberg(Cornell University)
Cited by 864
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k